Physician perspectives in the management of psoriasis and psoriatic arthritis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 10, 2015, Pages 2002-2010

  Van De Kerkhof, P C M ^a   Reich, K ^b   Kavanaugh, A ^c   Bachelez, H ^d   Barker, J ^e   Girolomoni, G ^f   Langley, R G ^g   Paul, C F ^h   Puig, L ⁱ   Lebwohl, M G ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DERMATOLOGIKUM HAMBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF VERONA   (Italy)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PSORALEN; STEROID; ANTIRHEUMATIC AGENT; DERMATOLOGICAL AGENT;

ARTHRALGIA; BIOLOGICAL THERAPY; CANADA; DAILY LIFE ACTIVITY; DERMATOLOGIST; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL WELL BEING; EUROPE; FRANCE; GERMANY; HEALTH CARE NEED; HEALTH SURVEY; HUMAN; ITALY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; NORTH AMERICA; PATIENT CARE; PATIENT MONITORING; PATIENT SATISFACTION; PERCEPTION; PHYSICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REVIEW; RHEUMATOLOGY; SOCIAL WELL BEING; SPAIN; STEROID THERAPY; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; UNITED KINGDOM; UNITED STATES; WELLBEING; ARTHRITIS, PSORIATIC; CLINICAL PRACTICE; DERMATOLOGY; EMOTION; HEALTH PERSONNEL ATTITUDE; INTERDISCIPLINARY COMMUNICATION; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT CARE PLANNING; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL PARTICIPATION; STATISTICS AND NUMERICAL DATA;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL PRODUCTS; CANADA; DERMATOLOGIC AGENTS; DERMATOLOGY; EMOTIONS; EUROPE; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE PLANNING; PRACTICE PATTERNS, PHYSICIANS'; PSORIASIS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL PARTICIPATION; UNITED STATES;

EID: 84942295796     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13150     Document Type: Review

References (16)

1. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M,. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
2. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60: 218-224.
3. Menter A, Gottlieb A, Feldman SR, et al., Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
4. Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A,. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001; 15: 20-23.
5. Rachakonda TD, Schupp CW, Armstrong AW,. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70: 512-516.
6. Ferrandiz C, Carrascosa JM, Toro M,. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr 2014; 105: 504-509.
7. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P,. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl 2): ii14-ii17.
8. Lebwohl MG, Bachelez H, Barker J, et al., Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871-881.
9. Armstrong AW, Schupp C, Bebo B,. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology 2012; 225: 121-126.
10. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W,. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009; 7: 25.
11. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M,. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57: 957-962.
12. Nast A, Reytan N, Rosumeck S, Erdmann R, Rzany B,. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008; 22: 1337-1342.
13. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG,. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013; 149: 1180-1185.
14. Mease PJ, Gladman DD, Papp KA, et al., Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013; 69: 729-735.
15. Maza A, Richard MA, Aubin F, et al., Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol 2012; 167: 643-648.
16. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.